Previous 10 | Next 10 |
2024-01-10 07:53:46 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris to slash 46% of workforce as it reprioritizes drug programs Aclaris Therapeutics announces patent license agreement with Sun Pharma for a...
- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777 Was Well Tolerated - WAYNE, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) --...
2023-12-20 10:00:08 ET More on Health Care Select Sector SPDR XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble For further details see: ...
2023-12-19 17:07:01 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris Therapeutics announces patent license agreement with Sun Pharma ...
- ATI-1777 Phase 2a Trial Results Published in JID Innovations - - ATI-1777 Phase 2b Trial Topline Data Anticipated in January 2024 - - Aclaris Announces Reduction in Workforce - WAYNE, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS),...
2023-12-18 15:30:01 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for ACRS on December 18, 2023 04:01PM ET. The previous analyst recommendation was Underperform. ACRS was trading at $0.9377 at issue of the analyst recommendation. The overall analyst conse...
2023-12-12 08:25:49 ET Summary Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early ...
2023-12-06 14:48:10 ET Penny Stocks – How News Makes These Small Caps Soar or Plunge Penny stocks , securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks require...
2023-12-05 17:10:33 ET Penny stocks , defined as those trading under $5 per share, offer unique opportunities. With low prices and the potential for high percentage returns, it’s understandable why penny stocks attract interest from new traders. However, diving into penny...
2023-12-05 16:05:02 ET More on Aclaris Therapeutics Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer Aclaris plummets as mid-stage trial for arthritis therapy fails ...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...